NASH/MASH的Vimgreen实验药物 获得了中国批准 开始人类试验 Vimgreen's experimental drug for NASH/MASH gets Chinese approval to begin human trials.

Vimgreen的A2AR实验性A2AR对抗体已经得到中国疾病防治中心的批准,开始临床试验,治疗非酒精类牛头类肝炎(NASH)和新陈代谢性机能失调相关胃类肝炎(MASH),这是该药物发展的关键一步。 Vimgreen's experimental A2AR antagonist has received approval from China's CDE to begin clinical trials for treating non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH), marking a key step in the drug's development. 批准允许公司对人体治疗进行测试,可能对影响全世界数百万人的病情产生影响。 The approval allows the company to test the therapy in humans, with potential implications for a condition affecting millions worldwide.